OtherNorth America Alzheimer’s Disease Drug Market by Manufacturers, Countries, Type and Application, Forecast to 2022

  • RnM1228422
  • |
  • 5 May, 2017
  • |
  • Global
  • |
  • 115 pages
  • |
  • GIR (GlobalInfoResearch)
  • |
  • Other

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

Scope of the Report:
This report focuses on the Alzheimer’s Disease Drug in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application.

Market Segment by Manufacturers, this report covers
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck.

Market Segment by Countries, covering
United States
Canada
Mexico

Market Segment by Type, covers
Donepezil
Memantine
Rivastigmine

Market Segment by Applications, can be divided into
Early to Moderate Stages
Moderate to Severe Stages

There are 15 Chapters to deeply display the North America Alzheimer’s Disease Drug market.

Chapter 1, to describe Alzheimer’s Disease Drug Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;

Chapter 2, to analyze the manufacturers of Alzheimer’s Disease Drug, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;

Chapter 4, to show the North America market by countries, covering United States, Canada and Mexico, with sales, revenue and market share of Alzheimer’s Disease Drug, for each country, from 2012 to 2017;

Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2012 to 2017;

Chapter 7, 8 and 9, to analyze the segment market in United States, Canada and Mexico, by manufacturers, type and application, with sales, price, revenue and market share by manufacturers, types and applications;

Chapter 10, Alzheimer’s Disease Drug market forecast, by countries, type and application, with sales, price and revenue, from 2017 to 2022;

Chapter 11, to analyze the manufacturing cost, key raw materials and manufacturing process etc.

Chapter 12, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);

Chapter 13, to describe sales channel, distributors, traders, dealers etc.

Chapter 14 and 15, to describe Alzheimer’s Disease Drug Research Findings and Conclusion, Appendix, methodology and data source

Table of Contents
1 Market Overview
1.1 Alzheimer’s Disease Drug Introduction
1.2 Market Analysis by Type
1.2.1 Donepezil
1.2.2 Memantine
1.2.3 Rivastigmine
1.3 Market Analysis by Applications
1.3.1 Early to Moderate Stages
1.3.2 Moderate to Severe Stages
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2012-2022)
1.4.2 Mexico Status and Prospect (2012-2022)
1.4.3 Canada Status and Prospect (2012-2022)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Allergan
2.1.1 Profile
2.1.2 Alzheimer’s Disease Drug Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Allergan Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.4 Business Overview
2.1.5 Allergan News
2.2 Eisai
2.2.1 Profile
2.2.2 Alzheimer’s Disease Drug Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Eisai Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.4 Business Overview
2.2.5 Eisai News
2.3 Novartis
2.3.1 Profile
2.3.2 Alzheimer’s Disease Drug Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Novartis Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.4 Business Overview
2.3.5 Novartis News
2.4 Daiichi Sankyo
2.4.1 Profile
2.4.2 Alzheimer’s Disease Drug Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Daiichi Sankyo Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.4 Business Overview
2.4.5 Daiichi Sankyo News
2.5 Merz Pharma
2.5.1 Profile
2.5.2 Alzheimer’s Disease Drug Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Merz Pharma Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.4 Business Overview
2.5.5 Merz Pharma News
2.6 Pfizer
2.6.1 Profile
2.6.2 Alzheimer’s Disease Drug Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Pfizer Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.4 Business Overview
2.6.5 Pfizer News
2.7 Johnson & Johnson
2.7.1 Profile
2.7.2 Alzheimer’s Disease Drug Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Johnson & Johnson Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.4 Business Overview
2.7.5 Johnson & Johnson News
2.8 Lundbeck.
2.8.1 Profile
2.8.2 Alzheimer’s Disease Drug Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Lundbeck. Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.4 Business Overview
2.8.5 Lundbeck. News
3 North America Alzheimer’s Disease Drug Market Competition, by Manufacturer
3.1 North America Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 North America Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 North America Alzheimer’s Disease Drug Price by Manufacturers (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Alzheimer’s Disease Drug Manufacturer Market Share
3.4.2 Top 5 Alzheimer’s Disease Drug Manufacturer Market Share
3.5 Market Competition Trend
4 North America Alzheimer’s Disease Drug Market Analysis by Countries
4.1 North America Alzheimer’s Disease Drug Sales Market Share by Countries
4.2 North America Alzheimer’s Disease Drug Sales by Countries (2012-2017)
4.3 North America Alzheimer’s Disease Drug Revenue (Value) by Countries (2012-2017)
5 North America Market Segmentation Alzheimer’s Disease Drug by Type
5.1 North America Alzheimer’s Disease Drug Sales, Revenue and Market Share by Type (2012-2017)
5.1.1 North America Alzheimer’s Disease Drug Sales and Market Share by Type (2012-2017)
5.1.2 North America Alzheimer’s Disease Drug Revenue and Market Share by Type (2012-2017)
5.2 Donepezil Sales Growth and Price
5.2.1 North America Donepezil Sales Growth (2012-2017)
5.2.2 North America Donepezil Price (2012-2017)
5.3 Memantine Sales Growth and Price
5.3.1 North America Memantine Sales Growth (2012-2017)
5.3.2 North America Memantine Price (2012-2017)
5.4 Rivastigmine Sales Growth and Price
5.4.1 North America Rivastigmine Sales Growth (2012-2017)
5.4.2 North America Rivastigmine Price (2012-2017)
6 North America Market Segmentation Alzheimer’s Disease Drug by Application
6.1 North America Alzheimer’s Disease Drug Sales Market Share by Application (2012-2017)
6.2 Early to Moderate Stages Sales Growth (2012-2017)
6.3 Moderate to Severe Stages Sales Growth (2012-2017)
7 United States Alzheimer’s Disease Drug Sales, Revenue, by Type, Application and Manufacturers
7.1 United States Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2012-2017)
7.2 United States Alzheimer’s Disease Drug Sales and Market Share by Type
7.3 United States Alzheimer’s Disease Drug Sales by Application (2012-2017)
7.4 United States Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer
7.4.1 United States Alzheimer’s Disease Drug Sales and Market Share by Manufacturer
7.4.2 United States Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer
7.5 United States Alzheimer’s Disease Drug Export and Import (2012-2017)
8 Canada Alzheimer’s Disease Drug Sales, Revenue, by Type, Application and Manufacturers
8.1 Canada Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2012-2017)
8.2 Canada Alzheimer’s Disease Drug Sales and Market Share by Type
8.3 Canada Alzheimer’s Disease Drug Sales by Application (2012-2017)
8.4 Canada Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer
8.4.1 Canada Alzheimer’s Disease Drug Sales and Market Share by Manufacturer
8.4.2 Canada Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer
8.5 Canada Alzheimer’s Disease Drug Export and Import (2012-2017)
9 Mexico Alzheimer’s Disease Drug Sales, Revenue, by Type, Application and Manufacturers
9.1 Mexico Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2012-2017)
9.2 Mexico Alzheimer’s Disease Drug Sales and Market Share by Type
9.3 Mexico Alzheimer’s Disease Drug Sales by Application (2012-2017)
9.4 Mexico Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer
9.4.1 Mexico Alzheimer’s Disease Drug Sales and Market Share by Manufacturer
9.4.2 Mexico Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer
9.5 Mexico Alzheimer’s Disease Drug Export and Import (2012-2017)
10 Alzheimer’s Disease Drug Market Forecast (2017-2022)
10.1 North America Alzheimer’s Disease Drug Sales, Revenue and Growth Rate (2017-2022)
10.2 Alzheimer’s Disease Drug Market Forecast by Countries (2017-2022)
10.2.1 United States Alzheimer’s Disease Drug Forecast (2017-2022)
10.2.2 Canada Alzheimer’s Disease Drug Forecast (2017-2022)
10.2.3 Mexico Alzheimer’s Disease Drug Forecast (2017-2022)
10.3 Alzheimer’s Disease Drug Market Forecast by Type (2017-2022)
10.4 Alzheimer’s Disease Drug Market Forecast by Application (2017-2022)
11 Alzheimer’s Disease Drug Manufacturing Cost Analysis
11.1 Alzheimer’s Disease Drug Key Raw Materials Analysis
11.1.1 Key Raw Materials
11.1.2 Price Trend of Key Raw Materials
11.1.3 Key Suppliers of Raw Materials
11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Alzheimer’s Disease Drug
12 Industrial Chain, Sourcing Strategy and Downstream Buyers
12.1 Alzheimer’s Disease Drug Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Alzheimer’s Disease Drug Major Manufacturers in 2016
12.4 Downstream Buyers
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Analyst Introduction
15.3 Data Source

captcha
Please enter code
captcha
Please enter code

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

captcha
Please enter code

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$4,480.00
$8,960.00
3,008.32
6,016.64
4,122.50
8,244.99
542,707.20
1,085,414.40
297,084.03
594,168.06
Add To Cart Credit card Logo

Related Reports


Reason to Buy